{"id":"tacrolimus-prograf","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nephrotoxicity/renal dysfunction"},{"rate":"30-50","effect":"Hypertension"},{"rate":"15-30","effect":"Hyperglycemia/new-onset diabetes"},{"rate":"10-25","effect":"Neurotoxicity (tremor, headache, paresthesia)"},{"rate":"20-40","effect":"Infections"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"10-15","effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). By preventing NFAT translocation to the nucleus, tacrolimus blocks the transcription of IL-2 and other cytokines required for T-cell activation and proliferation. This potent immunosuppression makes it effective for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:58.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney, heart, and liver transplant recipients"},{"name":"Atopic dermatitis (topical formulation)"},{"name":"Severe refractory uveitis"},{"name":"Autoimmune conditions (off-label use)"}]},"trialDetails":[{"nctId":"NCT03321656","phase":"PHASE2, PHASE3","title":"Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile","status":"RECRUITING","sponsor":"Roberto Gedaly","startDate":"2019-03-28","conditions":"End Stage Renal Disease","enrollment":78},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT06918990","phase":"PHASE2","title":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-15","conditions":"Kidney Transplant Rejection","enrollment":25},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT06529536","phase":"PHASE4","title":"Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-08-05","conditions":"Solid Organ Transplant","enrollment":45},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT06001385","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2023-12-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia","enrollment":313},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT03178149","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2018-07-13","conditions":"Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT03979365","phase":"PHASE4","title":"Envarsus XR Compared to Immediate Release Tacrolimus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-18","conditions":"Kidney Transplant Recipients","enrollment":261},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT01780844","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-03-05","conditions":"Kidney Transplantation","enrollment":149},{"nctId":"NCT02882828","phase":"PHASE4","title":"PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2016-10","conditions":"Allograft","enrollment":134},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT05856994","phase":"PHASE1","title":"Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-09-19","conditions":"Burn Injury","enrollment":18},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT03373227","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2017-12-04","conditions":"Heart Transplant Rejection, Graft Failure, Compliance, Patient","enrollment":50},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT03076151","phase":"PHASE4","title":"Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2018-02-12","conditions":"Transplantation, Kidney, Pharmacokinetic","enrollment":30},{"nctId":"NCT04945785","phase":"","title":"\" SAVE Study (Switch AdVagraf® to Envarsus®) for Fast Metabolizers Kidney Transplant Recipients\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-07-28","conditions":"Renal Transplant Failure","enrollment":226},{"nctId":"NCT07042035","phase":"","title":"Study of Tacrolimus Melt-Dose® for Lung Transplant Patients","status":"RECRUITING","sponsor":"Chiesi España, S.A.U.","startDate":"2024-10-29","conditions":"Lung Trasplant, Lung Transplantation","enrollment":240},{"nctId":"NCT01350245","phase":"PHASE2","title":"Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia","enrollment":28},{"nctId":"NCT06960824","phase":"","title":"Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Chiesi SAS","startDate":"2025-05","conditions":"Chronic Renal Disease","enrollment":165},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT01532635","phase":"PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-03","conditions":"Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT03769298","phase":"PHASE2, PHASE3","title":"CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2019-02-27","conditions":"Kidney Pancreas Transplantation","enrollment":20},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT06445205","phase":"","title":"Utilising Volumetric Absorptive Microsampling (VAMS) Technology to Monitor Tacrolimus and Creatinine","status":"SUSPENDED","sponsor":"Lancashire Teaching Hospitals NHS Foundation Trust","startDate":"2024-02-13","conditions":"Kidney Transplant Rejection, Kidney Replacement","enrollment":50},{"nctId":"NCT04720326","phase":"PHASE4","title":"Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Geissler","startDate":"2020-12-23","conditions":"Prophylaxis Against Liver Transplant Rejection","enrollment":268},{"nctId":"NCT03823768","phase":"PHASE4","title":"Envarsus Neurotoxicity Burden in Liver Transplant Patients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2020-01-31","conditions":"Neurotoxicity, Liver Transplant; Complications","enrollment":30},{"nctId":"NCT05153915","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2021-12-30","conditions":"Liver Transplantation, Kidney Transplantation","enrollment":56},{"nctId":"NCT05152628","phase":"PHASE4","title":"A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2022-01-11","conditions":"Liver Transplantation, Kidney Transplantation","enrollment":55},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT02723591","phase":"PHASE4","title":"To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-09-09","conditions":"Kidney Transplantation","enrollment":599},{"nctId":"NCT04489134","phase":"PHASE2","title":"P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2022-02-15","conditions":"Pharmacokinetics","enrollment":27},{"nctId":"NCT02880293","phase":"NA","title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-08-23","conditions":"Hematologic Malignancy","enrollment":44},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT00717470","phase":"PHASE4","title":"A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05-14","conditions":"Kidney Transplantation","enrollment":1252},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01371331","phase":"PHASE4","title":"A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-06-09","conditions":"Kidney Transplantation, Heart Transplantation, Liver Transplantation","enrollment":52},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT02147938","phase":"","title":"A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-07-17","conditions":"Renal Transplantation","enrollment":578},{"nctId":"NCT01371344","phase":"PHASE4","title":"A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-06-24","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":47},{"nctId":"NCT01763580","phase":"PHASE4","title":"A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2012-07-16","conditions":"MCNS, Minimal Change Nephrotic Syndrome (MCNS)","enrollment":144},{"nctId":"NCT02161237","phase":"PHASE4","title":"Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-06-26","conditions":"Kidney Transplantation","enrollment":73},{"nctId":"NCT01882322","phase":"PHASE4","title":"A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2013-01-30","conditions":"de Novo Liver Transplant Subjects","enrollment":36},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT01316133","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2011-04-19","conditions":"Lupus Nephritis","enrollment":37},{"nctId":"NCT01410747","phase":"","title":"A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-04-10","conditions":"Lupus Nephritis","enrollment":1484},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT02160054","phase":"","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-15","conditions":"the Maintenance Phase After Kidney Transplantation","enrollment":289},{"nctId":"NCT02143479","phase":"","title":"A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-06-18","conditions":"Liver Transplantation","enrollment":398},{"nctId":"NCT03410654","phase":"EARLY_PHASE1","title":"Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-10-24","conditions":"Kidney Transplant; Complications","enrollment":28},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT03794492","phase":"PHASE4","title":"Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-03-31","conditions":"Kidney Transplant","enrollment":169},{"nctId":"NCT06268769","phase":"PHASE4","title":"Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs","status":"RECRUITING","sponsor":"Edward Geissler","startDate":"2024-03-09","conditions":"Immunosuppression","enrollment":300},{"nctId":"NCT04078750","phase":"NA","title":"PLATO - Medication Adherence in Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2019-09-10","conditions":"Kidney Disease, Chronic, Medication Adherence, Renal Disease","enrollment":99},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT05396898","phase":"PHASE4","title":"Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2020-12-16","conditions":"Posttransplant Diabetes Mellitus","enrollment":44},{"nctId":"NCT04496401","phase":"PHASE4","title":"PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2020-09-28","conditions":"Kidney Transplantation, Pancreas Transplantation, Diabetes","enrollment":25},{"nctId":"NCT00519116","phase":"PHASE4","title":"Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Kidney Transplantation","enrollment":150},{"nctId":"NCT04936282","phase":"PHASE4","title":"Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)","status":"UNKNOWN","sponsor":"Fundación Canaria de Investigación Sanitaria","startDate":"2022-07-05","conditions":"Kidney Transplant Failure and Rejection","enrollment":80},{"nctId":"NCT04048161","phase":"PHASE4","title":"Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome","status":"COMPLETED","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2019-11-12","conditions":"Nephrotic Syndrome in Children","enrollment":270},{"nctId":"NCT01172418","phase":"PHASE4","title":"Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":"Transplant; Failure, Kidney","enrollment":200},{"nctId":"NCT00533624","phase":"PHASE2, PHASE3","title":"Myfortic vs. Cellcept in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-12","conditions":"End Stage Renal Disease","enrollment":150},{"nctId":"NCT06057545","phase":"PHASE3","title":"Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2023-04-25","conditions":"Pediatric Kidney Disease","enrollment":30},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT04725682","phase":"PHASE1","title":"Bioequivalence Study of Tacrolimus in Healthy Volunteers","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-01-05","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT06035614","phase":"NA","title":"Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children","status":"COMPLETED","sponsor":"Clarteis","startDate":"2022-10-01","conditions":"Vitiligo, Pediatric ALL, Dermatologic Disease","enrollment":50},{"nctId":"NCT00905515","phase":"PHASE4","title":"Optima: Optimizing Prograf Therapy in Maintenance Allografts II","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2003-08","conditions":"Kidney Transplantation","enrollment":63},{"nctId":"NCT05385432","phase":"PHASE3","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-09-12","conditions":"Renal Transplant Rejection, Induction Therapy","enrollment":244},{"nctId":"NCT05324618","phase":"PHASE4","title":"Tacrolimus Versus Hydrocortisone in Atopic Dermatitis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-05-15","conditions":"Atopic, Dermatitis","enrollment":200},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT02341274","phase":"PHASE1","title":"Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-11-11","conditions":"Bioequivalence","enrollment":24},{"nctId":"NCT04903054","phase":"PHASE2","title":"Selective CD28 Blockade in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-01-10","conditions":"Kidney Transplantation, Renal Transplant Recipients","enrollment":""},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT03614221","phase":"PHASE2","title":"Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-06-03","conditions":"Atopic Dermatitis","enrollment":22},{"nctId":"NCT03266393","phase":"PHASE4","title":"Envarsus XR® in Adolescent Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2019-01-15","conditions":"Kidney Transplantation, Renal Transplantation, Grafting, Kidney","enrollment":28},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT02440464","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT00406393","phase":"PHASE3","title":"Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2006-11","conditions":"Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic","enrollment":304},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT02918292","phase":"PHASE2","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-07-03","conditions":"Severe Aplastic Anemia","enrollment":32},{"nctId":"NCT02495077","phase":"PHASE2","title":"Effects of Inhibiting Early Inflammation in Kidney Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-02","conditions":"Kidney Transplant","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf"],"phase":"marketed","status":"active","brandName":"Tacrolimus (Prograf®)","genericName":"Tacrolimus (Prograf®)","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses. Used for Prevention of organ rejection in kidney, heart, and liver transplant recipients, Atopic dermatitis (topical formulation), Severe refractory uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}